XERS
Xeris Pharmaceuticals Inc
NASDAQ: XERS · HEALTHCARE · BIOTECHNOLOGY
$6.13
+1.74% today
Updated 2026-04-30
Market cap
$1.04B
P/E ratio
0.00
P/S ratio
3.56x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$4 – $10
Volume
1.9M
Xeris Pharmaceuticals Inc (XERS) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.19%
Operating margin
19.60%
ROE
-617.00%
ROA
4.40%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2016 | $1.07M | $-13.21M | 99.26% | -1,230.79% | -1,228.74% |
| 2017 | $1.56M | $-26.55M | 99.74% | -1,711.38% | -1,706.56% |
| 2018 | $2.46M | $-60.08M | 98.30% | -2,407.46% | -2,437.32% |
| 2019 | $2.72M | $-125.58M | 41.11% | -4,495.96% | -4,613.52% |
| 2020 | $2.72M | $-125.58M | 41.11% | -4,495.96% | -4,613.52% |
| 2021 | $49.59M | $-122.72M | 73.14% | -232.22% | -247.48% |
| 2022 | $110.25M | $-94.66M | 79.47% | -74.32% | -85.86% |
| 2023 | $163.91M | $-62.26M | 82.52% | -26.85% | -37.98% |
| 2024 | $203.07M | $-54.84M | 81.86% | -16.57% | -27.00% |
| 2025 | $291.85M | $554000.00 | 81.70% | 8.53% | 0.19% |